A LoDoCo2 subanalysis suggests that the benefits of low-dose colchicine are consistent if initiated months or years following acute coronary syndrome (ACS) among patients with stable coronary artery disease.

In the parent study, it was noted that the addition of colchicine 0.5 mg a day to standard care led to a reduction in the risk of the primary endpoint (composite of cardiovascular (CV) death, myocardial infarction (MI), ischemic stroke, or ischemia-driven coronary revascularization) by 31%, compared to placebo. The new analysis revealed that the drug was equally effective in diminishing the risk of the primary endpoint in patients without previous ACS, recent ACS (6-24 months), remote ACS (2-7 years), or very remote ACS (>7 years), and there appeared to be no interaction between the groups. The incidence of the primary endpoint per 100 person-years and hazard ratios (HR) for the study groups with colchicine and placebo were found to be - No previous ACS: 2.8 vs 3.4, HR 0.81; Recent ACS: 2.4 vs 3.3, HR 0.75; Remote ACS: 1.8 vs 3.2, HR 0.55; and Very remote ACS: 3.0 vs 4.3, HR 0.70. The study is published in the Journal of the American College of Cardiology… (Medscape)